Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
xmab save search
Emerging Dupilumab (Dupixent) Drug Insights and Market Forecasts, 2032: A mAb Targeting the a-chain of the Interleukin (IL)-4 Receptor - Focus on US, Germany, France, Italy, Spain, UK, and Japan
Published: 2023-11-21 (Crawled : 03:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.13%
H: 1.36%
C: 0.38%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug japan market
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
Published: 2023-11-03 (Crawled : 18:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 1.77%
H: 4.61%
C: 3.65%
xmab research preclinical meeting
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-03-14 (Crawled : 21:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 1.2%
H: 0.17%
C: -1.67%
cd28 xmab research preclinical antibody meeting association cancer
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
Published: 2023-01-05 (Crawled : 12:00) - prnewswire.com
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.27%
H: 1.53%
C: 1.12%
xmab sciences drug collaboration antibody life
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
Published: 2022-11-10 (Crawled : 15:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 3.49%
H: 1.51%
C: -0.03%
xmab meeting study
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
Published: 2022-11-07 (Crawled : 22:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.56%
H: 1.14%
C: -0.74%
xmab study
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
Published: 2022-08-02 (Crawled : 11:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.32%
H: 5.09%
C: 3.9%
xmab sciences collaboration life license agreement
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
xmab antibody phase 1
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-24 (Crawled : 12:20) - prnewswire.com
TCON | $1.875 3.02% 2.93% 55K
|
Health Technology
|
| O: 1.1%
H: 2.19%
C: -1.64%
yh003 biopharma trials
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Published: 2022-04-08 (Crawled : 18:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.6%
H: 0.46%
C: -2.39%
xmab research preclinical cancer pre-clinical
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Published: 2022-03-08 (Crawled : 00:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
xmab america program research preclinical cancer pre-clinical
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
antibody preclinical pre-clinical
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.98%
H: 0.63%
C: -0.48%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 2.87%
H: 5.64%
C: 5.37%
treatment collaboration antibody license t-cell
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
Published: 2021-10-01 (Crawled : 13:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
phase 1 research
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
Published: 2021-03-11 (Crawled : 06:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 0.0%
H: 3.91%
C: 3.85%
cancer antibody research preclinical pre-clinical
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.